Drug Trial Radar · NCT02561988
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Last checked: Nov 20, 2026Latest source record: Mar 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Mar 10, 2016
Primary completion
Oct 5, 2022
Study completion Jan 19, 2023
Sponsor
- Lead sponsor
- Blueprint Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Sep 29, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult patients with advanced systemic mastocytosis and other relapsed or refractory myeloid malignancies. The study consists of 2 parts:, dose-escalation (Part 1) and expansion (Part 2).
Conditions
- Aggressive Systemic Mastocytosis
- Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease
- Mast Cell Leukemia
- Relapsed or Refractory Myeloid Malignancies
Interventions
AvapritinibDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) of avapritinib (also known as BLU-285)Time frame: During cycle 1 (28 days) of treatment
- Number of patients with adverse and serious adverse events and changes in physical findings, vital signs, clinical laboratory results and ECG findingsTime frame: Approximately 24 months
- Recommended Phase 2 dose (RP2D) of avapritinibTime frame: Approximately 24 months
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Stanford Cancer Institute
Stanford, California
University of Colorado Cancer Center
Denver, Colorado
Emory University
Atlanta, Georgia
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan Health System
Ann Arbor, Michigan
Mount Sinai Hospital
New York, New York
University of Pennsylvania
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Guy's Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.